JP2003523325A5 - - Google Patents

Download PDF

Info

Publication number
JP2003523325A5
JP2003523325A5 JP2001548102A JP2001548102A JP2003523325A5 JP 2003523325 A5 JP2003523325 A5 JP 2003523325A5 JP 2001548102 A JP2001548102 A JP 2001548102A JP 2001548102 A JP2001548102 A JP 2001548102A JP 2003523325 A5 JP2003523325 A5 JP 2003523325A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
abl
pdgf
acceptable salt
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001548102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523325A (ja
Filing date
Publication date
Priority claimed from IT1999MI002711A external-priority patent/ITMI992711A1/it
Application filed filed Critical
Publication of JP2003523325A publication Critical patent/JP2003523325A/ja
Publication of JP2003523325A5 publication Critical patent/JP2003523325A5/ja
Pending legal-status Critical Current

Links

JP2001548102A 1999-12-27 2000-12-22 受容体チロシンキナーゼ阻害剤とα１−酸性糖タンパク質結合性有機化合物との組合せ Pending JP2003523325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici
IT99A002711 1999-12-27
PCT/EP2000/013161 WO2001047507A2 (en) 1999-12-27 2000-12-22 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Publications (2)

Publication Number Publication Date
JP2003523325A JP2003523325A (ja) 2003-08-05
JP2003523325A5 true JP2003523325A5 (enExample) 2008-02-14

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001548102A Pending JP2003523325A (ja) 1999-12-27 2000-12-22 受容体チロシンキナーゼ阻害剤とα１−酸性糖タンパク質結合性有機化合物との組合せ

Country Status (18)

Country Link
US (2) US20030125343A1 (enExample)
EP (1) EP1250140B1 (enExample)
JP (1) JP2003523325A (enExample)
CN (1) CN1304005C (enExample)
AR (1) AR030179A1 (enExample)
AT (1) ATE432069T1 (enExample)
AU (1) AU2171901A (enExample)
BR (1) BR0016817A (enExample)
CA (1) CA2394944A1 (enExample)
CO (1) CO5271710A1 (enExample)
DE (1) DE60042283D1 (enExample)
ES (1) ES2326307T3 (enExample)
HK (1) HK1050993A1 (enExample)
IT (1) ITMI992711A1 (enExample)
PE (1) PE20010991A1 (enExample)
PT (1) PT1250140E (enExample)
TW (1) TWI246917B (enExample)
WO (1) WO2001047507A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223684A1 (en) * 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
CA2542007C (en) * 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003268185A1 (en) * 2003-08-25 2005-04-11 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
PL1720853T3 (pl) † 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
MXPA06015237A (es) 2004-06-29 2007-12-10 Amgen Inc Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
MX2007001399A (es) * 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
DE602006015994D1 (de) * 2005-06-23 2010-09-16 Novartis Ag Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
EP2397138B1 (en) * 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Aromatic amide derivatives as C-KIT kinase inhibitors
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
KR20100116607A (ko) 2008-01-11 2010-11-01 낫코 파마 리미티드 항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU6014900A (en) * 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
OA12118A (en) * 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.

Similar Documents

Publication Publication Date Title
CA2490907A1 (en) Amide derivative
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
PL392652A1 (pl) Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
CA2416274A1 (en) N-phenyl-2-pyrimidine-amine derivatives
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
CA2551529A1 (en) Amide derivative and medicine
EP1521749B8 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
UA94427C2 (ru) Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
KR20170007868A (ko) Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
KR100848197B1 (ko) 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물
AR031679A1 (es) Una composicion farmaceutica
JP2005527523A5 (enExample)
EA200400253A1 (ru) Применение соединения bibn4096bs в комбинации с другими лекарственными веществами против мигрени для лечения мигрени
RU2002118304A (ru) Способ подавления чувства страха
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
JP2002542281A5 (enExample)
TNSN06182A1 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
JP2007514699A5 (enExample)
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
DE602005013580D1 (de) Imidazoä4,5-cüpyridinverbindung und verfahren zur antiviralen behandlung
WO2009073146A3 (en) Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders